34results about How to "Enhance activity" patented technology

A fluid delivery apparatus for infusing medicinal fluids into a patient which is of a compact, low profile, laminate construction. The apparatus embodies a novel thermal expanding polymer material which uniquely functions as an internal energy source for expelling the medicinal fluids from the device. The apparatus can be used for subdermal, intradermal and intramuscular infusion of fluids and in one form of the invention, includes a novel delivery cannula having a body portion disposed within a circuitous channel formed within the base superstructure of the apparatus and a pierceable portion which extends outwardly from the base of the apparatus. By constructing the cannula in a circuitous configuration and dynamically connecting it to the base assembly, movement of the cannula relative to the base assembly is permitted thereby minimizing needle related tissue necrosis. The heat-expandable mass which is heated by the patient's body temperature in a manner to controllably expel fluid from the device uniquely functions to provide a conformable ullage within the reservoir of the device which will effectively avoid extended flow delivery rate trail-off at the end of the fluid delivery period. Further, the heat expandable mass can be specifically tailored to provide precise, predictable protocol delivery of the medicinal agent stored within the reservoir of the device.

Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.

The invention provides a synergistic oral liquid herbal composition falling under the category of "Asavas" and "Arishtas", useful for management of diabetes, said composition comprising a therapeutically effective amount of plant extracts, self-generated ethanol to the extent of 7 to 12% v / v and having not more than 1 to 3% w / w of sugar content and also provides a novel method for the manufacture of herbal compositions in liquid oral dosage form containing a limited amount of self generated alcohol.

The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.

Real time purification of contaminated common air is an unsolved consumer health problem inside residences and the workplace, and outside air pollution by industry and transportation. Currently popular consumer grade electrostatic air filters accumulate suspended contaminants onto accumulation plates which require subsequent disposal or cleaning of the highly concentrated contaminates, a maintenance requirement that creates new jeopardy to consumer health. Disclosed are a method and apparatus with several embodiments that structurally eradicate suspended particulates after they have been electrostatically migrated to a hollow, activated dismantling rod. The dismantling rod is typically composed of a durable, UV transmitting material, such as tetrafluoroethylene, or a current carrying metal mesh coated with tetrafluoroethylene, and further over-coated with active photocatalytic material that is energized to create on its surface powerful dismantling agents, including hydroxyl radicals, from natural ambient air elements. Microorganisms, smoke particles, industrial pollutants, odor molecules, and allergens are structurally dissociated into harmless protein fragments and natural molecules when they encounter the dismantling grid purifying agents. The decontamination phenomenon is amplified by imparting, or enhancing, either a negative or positive electrostatic charge to the suspended particles, as they enter the device, and using that to migrate the particles to the activated dismantling rod containing an internal, oppositely charged attraction screen. The method can be used to eradicate particles, including lethal pathogens, that may have a naturally occurring negative, positive, or electroneutral charge. Both contaminants and suspended water molecules are drawn to the dismantling rod in this manner, providing an enhanced supply of raw material from which the decontaminating agents are created. Any trace amounts of ozone molecules produced during the process are also attracted and dissociated back to oxygen within the device. The permanent photocatalytic coating does not require renewal or cleaning, and is designed to use UV energy in a bandwidth that also physically inactivates the replication defenses of passing microorganisms until they can be dismantled, whether in the first pass on during a subsequent air exchange pass. None of the powerful dismantling agents escape the device because of their short half lives; once their job is done all return to the natural elements from which they were made, creating no environmental harm. The method and apparatus are self cleaning and maintenance free.

A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to treat parasitic diseases is described. Examples of useful thiazine dyes are methylene blue, azure A, azure C, toluidine, and thionine. The preferred dye is methylene blue, administered orally twice a day. Since methylene blue absorbs in the red wavelengths, i.e., approximately 670 nm, which penetrates tissue much better than other lower wavelengths, light penetrating the skin to the capillaries at the surface can be used to enhance the activity of the dye. The thiazine dye can be provided in combination with other known antibiotics, anti-inflammatories, anti-parasitics, antifungals, and antivirals.

The present invention relates to methods for determining cellulolytic enhancing activity of a polypeptide, comprising: (a) incubating a cellulosic material with an enzyme composition comprising a cellobiose dehydrogenase and one or more (several) cellulolytic enzymes in the presence and absence of the polypeptide; and (b) measuring the release of sugar from the cellulosic material in the presence and absence of the polypeptide.

The present invention provides a use of an insulin for the manufacture of a medicament for treating or preventing diseases or disorders of adult brain. Also provided is a method for treating or preventing diseases or disorders of adult brain by administering an effective amount of an insulin to the brain. The diseases or disorders of adult brain are associated with tissue shrinkage or atrophy. The amount of the insulin administered is preferably from 0.001 Units per kg body weight per day up to 10 Units per kg body weight per day.

The present invention relates to novel derivatives of Andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of Andrographolide have the general formula (I) The andrographolide derivatives represented by general formula (I) are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis, other cardiovascular disorders, and can be used as antiviral, antimalarial, antibacterial, hepatoprotective, and immunomodulating agents and for treatment of other metabolic disorders.

To provide a pharmaceutically effective prophylactic / preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic / preventive agent for low-HDL cholesterolemia or arteriosclerosis.

The present invention relates to a composition for preventing or treating a nerve gas-induced disease comprising a phenyl carbamate compound and a method for preventing or treating a nerve gas-induced disease therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases caused by exposure to nerve gas.

The invention relates to five or four novel genes and the gene products thereof from Bacillus licheniformis and sufficiently similar genes and proteins which are involved in vivo in the formation of polyamino acids. The gene in question is ywsC, ywsC′, ywtA, ywtB and ywtD or proteins coded thereby. The gene ywsC, ywsC′, ywtA and ywtB can be used to improve biotechnological production methods by microorganisms, wherein they are functionally inactivated; the gene ywtD which codes for a peptide decomposing poly-gamma glutamate can, inversely, contribute to the improvement of biotechnological production methods by increased expression. Said genes can be used positively, preferably to result in a modification or decomposition of poly-gamma glutamate.

The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins.

This invention is in the area of phenylindoles that are useful for the treatment of HIV infection, and, in particular, phenylindoles that exhibit significant activity against resistant strains of HIV. The phenylindoles have at least two substituents other than hydrogen on the benzo ring of the indole function, preferably at the 4′ and 5′, 5′ and 6′ or the 5′ and 7′ positions, optionally in combination with disubstitution at positions 3″ and 5″ on the phenyl ring of the compound, and carboxamide containing moieties at position-2 on the indole group of the compound. Methyl is a preferred group for substitution on the phenyl ring. Preferred substituents for the benzo ring of the indole function include but are not limited to chlorine, fluorine, bromine, iodine, CF3, methoxy, CN, and NO2.

The invention as disclosed herein is a method and composition for the treatment of HIV in humans and other host animals, that includes the administration of an effective HIV treatment amount of a phenylindole as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier. The compounds of this invention either possess antiviral (i.e., anti-HIV) activity, or are metabolized to a compound that exhibits such activity.

The invention refers to fungal cells, and especially to oleaginous fungal cells that have been genetically modified to produce enzymes of the pyruvate dehydrogenase bypass route to enhance their lipid production. Especially the cells are modified to over-express genes encoding pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD) and / or acetyl-CoA synthetase (ACS), optionally together with a gene encoding diacylglycerol acyltransferase (DAT), or to express genes encoding PDC together with ALD and / or ACS. Methods of producing lipids, biofuels and lubricants using the modified fungi are also disclosed as well as expression cassettes useful therein. A new enzyme having phosholipid: diacylglycerol acyltransferase (PDAT)activity it and a polynucleotide encoding it are also disclosed, which are useful in the lipid production. A recombinant Cryptococcus cell and its construction is described.

Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and / or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFNα and IFNγ. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested. The polypeptides confirm direct involvement of tyrosine kinase in intracellular message transmission. Numerous diagnostic and therapeutic materials and utilities are also disclosed.

The invention may be broadly defined as the addition of Argon to FFPE procedures as an RNA stabilizing agent. Argon is an inert gas from the Noble gas group with low saturation concentrations in water. It is therefore highly surprising that Argon would have any effect on RNA stability in the presence of Formalin, or any other chemical. This property of Argon appears to be specific in that other inert gases fail to show any RNA stabilizing effect.

The present invention discloses a compound—‘ethyl gallate’ which can be used as an activity enhancer for enhancing the activity of antibiotic compositions and also overcoming drug resistance in bacteria. The compound was tested against gram negative, pathogenic bacteria viz. Pseudomonas aeruginosa and Klebsiella pneumoniae in combination with tetracycline, ciprofloxacin and chloramphenicol and found to be highly effective. The effect of the compound is due to its inhibitory action on the efflux pump of the bacteria, due to which even lower concentrations of the antibiotic compositions are highly effective in killing the bacteria. The compound thus offers the technical benefits of enhancing effects of antibiotic compositions at lower dosages and helping to overcome drug resistance in bacteria.

The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and / or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules.

The present invention provides a method of measuring the activity of neprilysin, etc. More specifically, the present invention provides a method of measuring the activity of neprilysin in nerve cells; a method of screening a protein, a peptide or a compound enhancing the activity or expression of neprilysin nerve cells by measuring the activity of neprilysin; a method of enhancing the activity or expression of neprilysin; and so on. Thus, the compound enhancing the activity and / or expression of neprilysin, which is obtained by the screening method characterized by using the method of measuring the activity of neprilysin in accordance with the present invention, is useful as a preventive and / or therapeutic agent for Alzheimer's disease. The method of measuring the activity of the present invention can be used for presymptoms diagnosis of Alzheimer's disease.

The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and / or respiratory chain complex III (RCCIII) deficiency.

A saccharide derivative represented by Chemical Formula (1) or (2), or a salt thereof, includes units of a monosaccharide linked to each other in a chainlike or cyclic manner through glycosidic bonding and has antimicrobial action. In the formulae, R1 represents an amino-containing structure; and n represents an integer of 3 or more. A saccharide derivative represented by Chemical Formula (5) or (6), or a salt thereof, includes units of a monosaccharide linked to each other in a chainlike or cyclic manner through glycosidic bonding and has antimicrobial activity enhancing action. In the formulae, R3 represents an amino-containing structure; R4 is selected from acetyl and propanoyl; and n represents an integer of 3 or more.

Provided are a composition for preventing or treating a bacterial infectious disease, comprising a phospholipase D2 (PLD2) inhibitor as an active ingredient and a method for treating the bacterial infectious disease using the same.Since the PLD2 inhibitor according to the present invention exhibits characteristics such as blocking of lung inflammation and liver inflammation, bactericidal activity through induction of NET production, effective maintenance of neutrophil mobility through the blocking of intracellular CXCR2 migration, and blocking of the production of inflammatory cytokines in bacterial infectious disease models, particularly, sepsis models, it is expected to be used as a therapeutic agent for sepsis or septic shock.

A method for preventing or reducing boar taint, a method of screening pigs to determine those more likely to have reduced boar taint and a method for screening substances that enhance skatole metabolism or androstenone in a pig, are disclosed These methods involve the use of the nuclear receptors constitutive androstane receptor, pregnane X receptor and farnesoid X receptor, which have been found to modulate the activity of the enzymes involved in skatole and / or androsterone metabolism

Biphenyl derivatives represented by the following formula (1):wherein R1 represents a C5-7 alkyl group, R2 represents a substituted or unsubstituted aromatic hydrocarbon, or cycloalkyl group, R3 represents a tetrazolyl group, —NHCOCF3, —NHSO2CF3 or —SO2NHCONHR4 in which R4 represents a substituted or unsubstituted aromatic hydrocarbon group, and Z represents a single bond, a C1-4 alkylene group or —SO2NH—, and salts thereof; and ACAT inhibitors and medicines containing them as active ingredients.The compounds according to the present invention possess excellent ACAT inhibitory activities, and are useful as preventives and / or therapeutics for diseases cased by the enhancement of ACAT activity, for example, hypercholesterolemia, atherosclerosis and the like.

The present invention relates to a pharmaceutical composition for treating hepatitis, liver fibrosis, and liver cancer, which comprises the following components in parts by weight: 0.15-10 parts of vinegar-baked bupleurum root polysaccharides or bupleurum root polysaccharides and 0.05-5 parts of a drug for treating hepatitis.

The present invention provides cytotoxic peptides, analogs thereof and fragments thereof, conjugates of said peptides, analogs or fragments as well as compositions comprising same. In addition, uses of these compounds and compositions in treating cancer are provided.

The present invention relates to novel benzodiazepinone compounds of Formulae (I)wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.